06.23.26 -- At BIO this week? Here are ADC & AOC Insights You Need

Across the industry, experts are noticing a shift from ADCs to X-drug conjugates (XDCs), evolving beyond antibody targeting technology to include peptides, oligos, small molecules, and/or viral components. These innovations present a new and complex manufacturing paradigm. To ensure a strategic competitive advantage, sponsors — both emerging biotechs and large pharma — must frontload risk identification and mitigation to protect their late-stage programs.

View antibody-oligonucleotide conjugate design strategies, highlighting antibody formats, linker strategies, and screening methods to optimize delivery, stability, and gene-targeting therapeutic performance.

Unlock the full potential of your ADCs & AOCs with an advanced site-specific conjugation platform that consistently delivers unmatched stability, homogeneity, and high-performing therapeutic outcomes.

Explore the fundamental science behind AOCs, including oligonucleotide synthesis, bioconjugation strategies, and the formulation challenges that arise from oligos’ inherent instability and charge properties.

See a real-world case study of an antibody-oligonucleotide conjugate (AOC) manufacturing first-in-human study. From process development, scale-up, GMP production, and analytical controls for efficient early-phase clinical material generation.

Learn how ADC conjugation platforms are being adapted for AOC development. Through real-world examples, watch how these programs come together from Fab intermediate development through GMP manufacture. If AOCs are part of your drug development pipeline, it’s worth a watch.